ArticleOpen veterinary journal2025
The effect of Hepato Forte in reducing hypercholesterolemia and DNA fragmentation induced by high cholesterol in male albino rats.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A "Hepato Forte" is essentially a built-in substance in plants that reconditions the functional aspects of the liver to act in manners like hepatoprotective drugs, aiding in liver repair and acting as an effect enhancer. Aim: The current investigation examines the protective benefits of Hepato Forte on (lipid profiles, DNA damage, and glycemic index) in healthy hypercholesterolemic and phosphatidylcholine-deficient male rats. Methods: Thirty-two adult male albino rats were included, and there were 8 rats in each group. The treatments were administered orally daily to the rats. The control group, labeled C, received distilled water, while the second group was given Hepato Forte alone at a dose of (500 mg/kg/day) via gavage needle. A third group received cholesterol at a dose of (10 g/day) via gavage needle, and the fourth group received both Hepato Forte at 500 mg/kg/day and high cholesterol at a dose of 10 g/day. Results: Routine administration of Hepato Forte led to a significant decline ( Conclusion: The findings of this research investigation show that Hepato Forte supplements and reducing DNA fragmentation play a critical protective role for the cardiovascular system and liver in adult male albino rats with hypercholesterolemia, effectively mitigating the adverse effects of high cholesterol on both the heart and liver.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.